The MDM X3 is an addition to the company’s portfolio of next-generation technologies designed to minimize risks associated with hip replacement surgery, including both primary and revision total hip arthroplasty patients. The device allows the surgeon to offer Stryker’s dual mobility technology to a broader patient population, including those who require advanced fixation.
The device is designed to enhance stability and jump distance, which could increase the range of motion in some patients.
Read the Stryker news release on clearance from the FDA.
Read other coverage on Stryker:
– Stryker Sells OP-1 Products to Olympus Corp. for $60M
– Stryker Signs Licensing Agreement With TriMed, Ending a 4-Year Patent Dispute
– Stryker Purchases Porex Surgical
